Clinical course of IPF in Italian patients during 12 months of observation: results from the FIBRONET observational study
| Autor: | Poletti V., Vancheri C., Albera C., Harari S., Pesci A., Metella R. R., Campolo B., Crespi G., Rizzoli S., Tomassetti S., Rottoli P., Bocchino M., Stanziola A. A., Luppi F., Sebastiani A., Lacedonia D., Vitulo P., Tavanti L., Vianello A., Saetta M., Marinari S., Pirina P., Valente S., Oggionni T., Gasparini S. |
|---|---|
| Přispěvatelé: | Poletti, V, Vancheri, C, Albera, C, Harari, S, Pesci, A, Metella, R, Campolo, B, Crespi, G, Rizzoli, S, Tomassetti, S, Rottoli, P, Bocchino, M, Stanziola, A, Luppi, F, Sebastiani, A, Lacedonia, D, Vitulo, P, Tavanti, L, Vianello, A, Saetta, M, Marinari, S, Pirina, P, Valente, S, Oggionni, T, Gasparini, S, Poletti, V., Vancheri, C., Albera, C., Harari, S., Pesci, A., Metella, R. R., Campolo, B., Crespi, G., Rizzoli, S., Tomassetti, S., Rottoli, P., Bocchino, M., Stanziola, A. A., Luppi, F., Sebastiani, A., Lacedonia, D., Vitulo, P., Tavanti, L., Vianello, A., Saetta, M., Marinari, S., Pirina, P., Valente, S., Oggionni, T., Gasparini, S. |
| Jazyk: | angličtina |
| Rok vydání: | 2021 |
| Předmět: |
Male
Vital capacity medicine.medical_specialty Time Factors Nintedanib Vital Capacity Idiopathic pulmonary fibrosis Disease Pirfenidone 03 medical and health sciences chemistry.chemical_compound FEV1/FVC ratio 0302 clinical medicine Internal medicine medicine Humans 030212 general & internal medicine Prospective Studies Prospective cohort study Observational Aged lcsh:RC705-779 Idiopathic pulmonary fibrosi business.industry Research Anti-Inflammatory Agents Non-Steroidal Antifibrotic therapy lcsh:Diseases of the respiratory system respiratory system medicine.disease Prognosis Lung function respiratory tract diseases 030228 respiratory system chemistry Italy Real-world Disease Progression Observational study Female business medicine.drug Follow-Up Studies |
| Zdroj: | Respiratory Research Respiratory Research, Vol 22, Iss 1, Pp 1-9 (2021) Poletti, V, Vancheri, C, Albera, C, Harari, S, Pesci, A, Metella, R R, Campolo, B, Crespi, G, Rizzoli, S & the FIBRONET study group 2021, ' Clinical course of IPF in Italian patients during 12 months of observation : results from the FIBRONET observational study ', Respiratory Research, vol. 22, no. 1, 66 . https://doi.org/10.1186/s12931-021-01643-w |
| DOI: | 10.1186/s12931-021-01643-w |
| Popis: | Background FIBRONET was an observational, multicentre, prospective cohort study investigating the baseline characteristics, clinical course of disease and use of antifibrotic treatment in Italian patients with idiopathic pulmonary fibrosis (IPF). Methods Patients aged ≥ 40 years diagnosed with IPF within the previous 3 months at 20 Italian centres were consecutively enrolled and followed up for 12 months, with evaluations at 3, 6, 9 and 12 months. The primary objective was to describe the clinical course of IPF over 12 months of follow-up, including changes in lung function measured by % predicted forced vital capacity (FVC% predicted). Results 209 patients (82.3% male, mean age 69.54 ± 7.43 years) were enrolled. Mean FVC% predicted was relatively preserved at baseline (80.01%). The mean time between IPF diagnosis and initiation of antifibrotic therapy was 6.38 weeks; 72.3% of patients received antifibrotic therapy within the first 3 months of follow-up, and 83.9% within 12 months of follow-up. Mean FVC% predicted was 80.0% at baseline and 82.2% at 12 months, and 47.4% of patients remained stable (i.e. had no disease progression) in terms of FVC% predicted during the study. Conclusions FIBRONET is the first prospective, real-life, observational study of patients with IPF in Italy. The short time between diagnosis and initiation of antifibrotic therapy, and the stable lung function between baseline and 12 months, suggest that early diagnosis and prompt initiation of antifibrotic therapy may preserve lung function in patients with IPF. Trial registration: NCT02803580 |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|